Polyrizon Initiates Human Study for NASARIX™ Allergy Blocker to Characterize Nasal Residence Time

On June 15, 2026, Polyrizon Ltd. (Nasdaq: PLRZ) announced the initiation of a human performance and characterization study for NASARIX™ (PL-14), its investigational intranasal hydrogel allergy blocker. The company has executed agreements with a leading European university medical center and a specialized clinical research organization (CRO) to conduct the study. The primary objective is to evaluate the nasal residence time of the NASARIX™ formulation in healthy participants, using endoscopic visualization and repeated measurements to determine how long the hydrogel remains in the nasal cavity. This data is critical for validating the product's protective barrier function and will support the company's regulatory strategy and planned submissions to the U.S. Food and Drug Administration (FDA). The study will be conducted under European MDR and GCP standards. Polyrizon’s proprietary Capture and Contain (C&C) technology aims to create a 'biological mask' to prevent allergens and viruses from contacting nasal epithelial tissue.